OLERUP SSP

HLA Wipe Test – Negative Control

Certificates

Page 1 of 2

102.101-01 - including *Taq* polymerase 102.101-01u - without *Taq* polymerase

Visit www.caredx.com for for "Instructions for Use" (IFU)

Lot No.: **0V2**

Lot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA Wipe Test – Negative Control

Product number:

102.101-01 - including Tag polymerase

Product number:

102.101-01u – without *Taq* polymerase

Lot number:

0V2

Expiry date:

2028-11-01

Number of tests:

96

Number of wells per test:

1-2

Well specification:

Well No.

Production No.

2023-544-01

The negative control primer solution has been tested in a dilution series of the corresponding PCR products, 1 to 10³ down to 1 to 10⁹. The Positive Control DNA has been tested with the HLA Wipe Test kit and gives rise to PCR amplicons.

The negative control primer pairs can detect contamination with the corresponding PCR products diluted 1 to 108, equivalent to 0.1 ng starting material.

Results of Quality Control: No false positive or false negative amplifications

obtained.

Date of approval: 2025-10-23

Approved by:

Production Quality Control

For In Vitro Diagnostic Use MA161 v01 CoA_DoC HLA Wipe Test Date: October 2025, Rev. No: 01

OLERUP SSP

HLA Wipe Test – Negative Control

Certificates

Page 2 of 2

102.101-01 – including *Taq* polymerase 102.101-01u – without *Taq* polymerase

Visit <u>www.caredx.com</u> for for "Instructions for Use" (IFU)

Lot No.: 0V2

Lot-specific information

Declaration of Conformity

Product name:

Olerup SSP® HLA Wipe Test - Negative Control

Product number:

102.101-01/01u

Lot number:

0V2

Intended use:

Detection of contamination with HLA amplicons.

Manufacturer:

CareDx AB

Franzéngatan 5

SE-112 51 Stockholm, Sweden **Phone:** +46-8-508 939 00

Fax: +46-8-717 88 18

We, CareDx AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) EN ISO 13485:2016, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex III, as transposed into the national laws of the Member States of the European Union.

The lot specific documentation is maintained at *CareDx* AB, Franzéngatan 5, SE-112 51 Stockholm, Sweden.

The Authorized Representative located within the Community is: CareDx AB.

Stockholm, Sweden Date:

2025-10-23

Quality Assurance

P. _____

Changes in revision R01 compared to R00:

^{1.} The HLA Wipe Test – Negative Control expiration date has been updated. This has been updated in the Product Insert, Worksheet, and Certificate of Analysis

